![\"Jas](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/07\/chambers-jas-web.jpg\")
<\/div><\/figure><\/div><\/div>Master of ceremonies<\/h2>\n\n
Jas Chambers<\/strong> Jas Chambers is an experienced leader working at the intersection of nature, science, business and policy with expertise in international science diplomacy including with the World Meteorological Organization, and the UNESCO Intergovernmental Oceanographic Commission (IOC). Dame Sally Davies<\/strong><\/strong><\/p>\n\n UK Special Envoy on AMR<\/p>\n\n Dame Sally Davies was appointed as the UK Government\u2019s Special Envoy on AMR in 2019. She is also the 40th Master of Trinity College, Cambridge University.\u00a0\u00a0<\/p>\n\n\n\n Dame Sally was the Chief Medical Officer for England and Senior Medical Advisor to the UK Government from 2011-2019. She is a leading figure in global health, having served as a member of the World Health Organisation (WHO) Executive Board 2014-2016, and as co-convener of the United Nations Inter-Agency Co-ordination Group (IACG) on Antimicrobial Resistance (AMR), reporting in 2019. In November 2020, Dame Sally was announced as a member of the new UN Global Leaders Group on AMR, serving alongside Heads of State, Ministers and prominent figures from around the world to advocate for action on AMR.\u00a0<\/p>\n\n\n\n In the 2020 New Year Honours, Dame Sally became the second woman (and the first outside the Royal family) to be appointed Dame Grand Cross of the Order of the Bath (GCB) for services to public health and research, having received her DBE in 2009.\u00a0<\/p>\n<\/details>\n<\/div><\/div> Hon. Julia Gillard AC<\/strong><\/strong><\/p>\n\n 27th<\/sup> Prime Minister of Australia Hon. Julia Gillard AC\u00a0served as the 27th Prime Minister of Australia (2010-13) and is a longstanding advocate for gender equity through her work with the Global Institute for Women\u2019s Leadership. She is currently Chair of the Wellcome Trust, one of the world\u2019s largest philanthropic organisations funding science to solve urgent health challenges. A passionate supporter of science and international collaboration, Julia brings a unique perspective to the AMR 2026 Summit.<\/p>\n<\/details>\n<\/div><\/div> Rt Hon. Helen Clark<\/strong><\/strong> ONZ<\/strong><\/p>\n\n Former Prime Minister of New Zealand<\/p>\n\n Former Administrator of UNDP<\/p>\n\n Helen Clark was Prime Minister of New Zealand from 1999\u20132008 and a Member of Parliament for 27 years. She advocated strongly for economic and social justice, sustainability and climate action, and for multilateralism.<\/p>\n\n\n\n Helen served two terms as Administrator of the United Nations Development Programme (UNDP) and as Chair of the United Nations Development Group from 2009-2017.<\/p>\n\n\n\n Earlier, Helen taught in the Political Studies Department of the University of Auckland, from which she had graduated with BA and MA (Hons) degrees.<\/p>\n\n\n\n Helen advocates for sustainable development, climate action, gender equality and women\u2019s leadership, peace and justice, and action on pressing global health issues. In July 2020, she was appointed by the Director-General of the World Health Organisation as Co-Chair of the Independent Panel for Pandemic Preparedness and Response. She chairs the boards of the Extractive Industries Transparency Initiative, the Partnership for Maternal, Newborn and Child Health, and other public good organisations and initiatives.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div>\n \u00a0<\/p>\n<\/div><\/div><\/div> Jeffrey Sturchio<\/strong><\/p>\n\n Co-chair, World Economic Forum\u2019s Global Future Council on AMR<\/p>\n\n Dr. Jeffrey L. Sturchio\u00a0is co-chair of the World Economic Forum\u2019s Global Future Council on Antimicrobial Resistance.\u00a0 \u00a0He is past Chairman and CEO at Rabin Martin, a global health strategy consulting firm, and former President and CEO of the Global Health Council. Before joining the Council in 2009, Dr. Sturchio was vice president of Corporate Responsibility at Merck & Co. Inc., and president of The Merck Company Foundation<\/p>\n\n\n\n He is currently also chairman of Friends of the Global Fight Against AIDS, TB and Malaria and chairman of the International Society for Urban Health, and a member of the boards of ACHAP, the American Institute of the History of Pharmacy, the Consortium for the History of Science, Technology, and Medicine, the Corporate Council for Africa, the Health Finance Institute, and the Science History Institute.\u00a0 He is also a senior associate at the Global Health Policy Center of the Center for Strategic and International Studies; a visiting scholar at the Institute for Applied Economics, Global Health, and the Study of Business Enterprise at Johns Hopkins University; and an advisor to amfAR, the Malaria Elimination Initiative, the TB Alliance, and the Partnership for Quality Medical Donations. \u00a0<\/p>\n\n\n\n Dr. Sturchio received his A.B. in history at Princeton University in 1973 and a PhD in the history & sociology of science at the University of Pennsylvania in 1981.\u00a0 His books include Noncommunicable Diseases in the Developing World: Addressing Gaps in Global Policy and Research<\/em>\u00a0(edited with L. Galambos and R. C. Whitehead, Johns Hopkins University Press, 2015), and The Road to Universal Health Coverage: Innovation, Equity and the New Health Economy <\/em>(edited with I. Kickbusch and L. Galambos\u200e, Johns Hopkins University Press, 2019).<\/p>\n\n\n\n <\/p>\n<\/details>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n Chris Cannan<\/strong><\/p>\n\n Australia\u2019s Ambassador for Global Health, <\/p>\n\n Chris is a senior career officer in the Department of Foreign Affairs and Trade (DFAT). He is currently Australia\u2019s Ambassador for Global Health and head of the department\u2019s Global Health Division. He has held diverse leadership roles across DFAT\u2019s operations, including Europe bilateral relations, corporate governance, public affairs, multilateral engagement, global health, protocol, human resources, and budget policy. Overseas he has served as Australian Ambassador to Israel, with earlier postings in Vienna and Manila. He has worked for the Global Fund to Fight AIDS, TB and Malaria in Geneva and was deployed with the ADF-led Bougainville Peace Monitoring Group in Papua New Guinea.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n<\/details>\n<\/div><\/div> Jean Pierre Nyemazi<\/strong><\/p>\n\n Quadripartite Joint Secretariat on AMR Dr Jean-Pierre Nyemazi serves as the Director of the Quadripartite (FAO, UNEP, WHO, WOAH) Joint Secretariat on Antimicrobial Resistance (AMR) and the Head of the Governance & Strategic Initiatives unit in the AMR Department at the WHO.<\/p>\n\n\n\n Leading a dedicated team, he advances multisectoral action against AMR, focusing on implementation of the UNGA Political Declaration on AMR and other Global commitments. His work also supports the functioning of the Global Governance Structures for AMR, including the Global Leaders Group on AMR, AMR Multistakeholder Partnership Platform. Before joining WHO, he held the position of Permanent Secretary of the Ministry of Health of Rwanda.<\/p>\n<\/details>\n<\/div>\n \u00a0<\/p>\n<\/div><\/div> Jane Halton<\/strong> AO PSM<\/strong><\/p>\n\n Chair, Coalition for Epidemic Preparedness Innovations, Institute of Health Metrics and Evaluation,\u00a0and Ngamuru Advisory<\/p>\n\n Jane Halton\u00a0is Chair of the Coalition for Epidemic Preparedness Innovations, the Institute for Health Metrics and Evaluation, and Ngamuru Advisory. She serves on the boards of Vet Partners, ASPI, Clayton Utz, and the Australian Film, Television and Radio School. Her previous roles include Chair of Suncorp Bank, Crown Resorts, and co-chair of the Global COVAX mechanism. A former Secretary of both the Department of Health and Department of Finance, Jane has deep expertise in public policy, finance, health, and ageing. Internationally, she has held senior roles with the World Health Organization and chaired the OECD Health Committee. She is an Honorary Professor at ANU and Adjunct Professor at the Universities of Sydney and Canberra. Jane has contributed significantly to public health, including tobacco control and communicable disease, and has received numerous honours including the Order of Australia and election to the US National Academy of Medicine.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div> Steve Wesselingh<\/strong><\/p>\n\n CEO, National Health and Medical Research Council (NHMRC) <\/p>\n\n Professor Wesselingh took up the position of the Chief Executive Officer at the National Health and Medical Research Council (NHMRC) in August 2023. <\/p>\n\n\n\n <\/p>\n<\/details>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n Fiona Reynolds<\/strong><\/p>\n\n President, FAIRR<\/p>\n\n Fiona Reynolds is an independent director and advisory board member working globally across the business and investor sectors on sustainability issues.<\/p>\n\n\n\n Fiona Reynolds joined FAIRR in 2024 as President. In this strategic advisory role, Fiona draws on her vast experience to help further increase the initiative\u2019s impact in the broader ecosystem of investors, funders, and partners.<\/p>\n\n\n\n Fiona has been recognised as one of the top 20 influential figures in global sustainability by Barron\u2019s magazine.<\/p>\n\n\n\n Fiona led the Principles for Responsible Investment (PRI) as CEO for almost a decade until early 2022.<\/p>\n\n\n\n She is the Chair of the UN Global Compact Network Australia and serves on the Board of Frontier Advisors, the Australian Sustainable Finance Institute, and the Achieve Foundation. She is on the Advisory Boards of Affirmative Investment Management, and ROC Partners. She chairs the ESG Advisory Board for Qualitas and is on the think tanks Climate Catalyst, and the UBS Sustainability and Impact Forum, as well the Advisory Committee for the NSW Commissioner for Anti-Slavery and the Australian Human Rights Institute.<\/p>\n<\/details>\n<\/div><\/div> Thanawat Tiensin<\/strong><\/p>\n\n Assistant Director-General, Chief Veterinarian, and Director of the Animal Production and Health Division, FAO<\/p>\n\n Dr. Thanawat Tiensin is the Assistant Director-General, Chief Veterinarian, and Director of the Animal Production and Health Division at FAO, leading global efforts on animal health, production, and One Health. He previously served as Minister (Agriculture) and Thailand\u2019s Permanent Representative to the UN Agencies in Rome (2018-2022) and chaired key FAO bodies, including the Committee on World Food Security. With extensive experience in international livestock policy, food security, and zoonotic disease prevention, apart from FAO, he has worked with key international agencies like IAEA, EU, ADB, and WOAH to strengthen One Health approaches across multiple countries.<\/p>\n<\/details>\n<\/div><\/div> Michael Kidd AO<\/strong><\/p>\n\n Chief Medical Officer, Australian Government Department of Health, Disability and Ageing<\/p>\n\n Professor Michael Kidd AO is Australia\u2019s Chief Medical Officer, based in the Australian Government Department of Health, Disability and Ageing.\u00a0 He is a general practitioner and a primary care and public health researcher, and has served as president of the Royal Australian College of General Practitioners, and president of the World Organization of Family Doctors.\u00a0 He is an elected Fellow of the Australian Academy of Health and Medical Sciences, and has held past research appointments at Monash University, the University of Sydney, Flinders University, the Australian National University, and the University of Toronto.\u00a0 He holds a current joint academic appointment as the Foundation Director of the International Centre for Future Health Systems at the University of New South Wales, and as Professor of Global Primary Care with the Nuffield Department of Primary Care Health Sciences at the University of Oxford.<\/p>\n<\/details>\n<\/div><\/div> Lord Jim O\u2019Neill<\/strong><\/p>\n\n Member of the House of Lords, Chair of the 2016 Review on Antimicrobial Resistance<\/p>\n\n Jim O\u2019Neill is a member of the House of Lords, sitting on the cross benches since he stepped down as Commercial Secretary to the Treasury in September 2016.<\/p>\n\n\n\n Jim is Chair of Northern Gritstone, a private investment company to support and expand start -up businesses, primarily originating from the Universities of Leeds, Manchester and Sheffield.\u00a0 He is Co-President of, and formerly Chair of, the Northern Powerhouse Partnership and is a member of the South Yorkshire Mayoral Economic Advisory Council. He chaired the Cities Growth Commission in the UK, which formed the basis for the Cameron government\u2019s approach to devolution and the concept of the Northern Powerhouse. \u00a0\u00a0<\/p>\n\n\n\n Jim is Chair of the NeoTest AMC working group launched by CGD to develop an advance market commitment for rapid diagnostic tests to combat neonatal sepsis in low and middle-income countries where the need is the greatest.\u00a0<\/p>\n\n\n\n He also still spends time on economic and finance of International Health Policy, having contributing to the UK G7 on Health, served on The Times\u00a0 Health Commission, and serving on the Monti Commission. Jim chaired an independent Review into AMR for the Cameron Government, helping drive HM Government\u2019s strategy as well as providing key input to the United Nations high level agreement in 2016. In 2018, Jim published a book, Superbugs, on AMR with two of his colleagues from the Review.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div>\n \u00a0<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n Rosemary Addis<\/strong> AM<\/strong><\/p>\n\n Founding Managing Partner, Mondiale Impact<\/p>\n\n Rosemary Addis is a globally recognised director and strategist at the forefront of innovation and investment for impact. She has led design and execution of ground-breaking investment vehicles, policy and pioneering organisations shaping market transformation for a more positive, sustainable future.\u00a0<\/p>\n\n\n\n Rosemary founded Mondiale Impact in 2022 with colleagues to support and challenge leaders in boardrooms and beyond to confront the new governance realities of our complex cotemporary context. She founded strategy firm Impact Strategist in 2003 and has advised and led on ground breaking strategies with clients including the World Banking Group, United Nations Development Programme, OECD Social Impact Investing Initiative, the World Economic Forum, governments and from major banks to institutional investors, corporations and foundations.\u00a0<\/p>\n\n\n\n \u00a0<\/p>\n\n\n\n \u00a0<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div> Lesley Ogilvie<\/strong><\/p>\n\n Director of the Secretariat at the Global AMR R&D Hub<\/p>\n\n Lesley is the Director of the Secretariat at the Global AMR R&D Hub, an international partnership dedicated to strengthening coordination, collaboration, and evidence-based decision-making in antimicrobial resistance (AMR) research and development. She holds a PhD in microbiology, with research expertise spanning infection biology and the human gut virome in health and disease. Before joining the Hub, Lesley held academic and research positions in microbial ecogenomics at institutions in the UK and Germany, including the Max Planck Institute of Molecular Genetics and the University of Brighton. She represents the Hub in advisory and expert groups convened by the World Health Organization (WHO), the European Commission, and other global stakeholders. Deeply committed to science-informed policymaking, she works to advance global collaboration and sustainable, evidence-driven solutions to address the growing challenge of AMR.<\/p>\n<\/details>\n<\/div><\/div> Henry Skinner<\/strong><\/p>\n\n CEO, AMR Action Fund<\/p>\n\n Henry Skinner, PhD, MS Bioethics, CEO of the AMR Action Fund,\u00a0has spent his career working to overcome the scientific and economic challenges associated with antimicrobial drug development. His cross-disciplinary expertise has been essential to shaping the AMR Action Fund\u2019s investment portfolio and policy priorities, with an emphasis on issues pertaining to R&D, innovative financing, and equitable access.\u00a0<\/p>\n\n\n\n Prior to joining the AMR Action Fund, Dr. Skinner held leadership positions across the pharmaceutical, biotech, and venture capital sectors. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois; an MS in Bioethics from Harvard Medical School; an MJur in Health Law, Policy, and Management from Texas A&M; and an MS and BS in Biology\/Biotechnology from Worcester Polytechnic Institute.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div>\n \u00a0<\/p>\n\n \u00a0<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n David Aanensen<\/strong><\/p>\n\n Director of the Centre for Genomic Pathogen Surveillance, Pandemic Science Institute, University of Oxford.<\/p>\n\n David is a Professor of Genomic and digital epidemiology and Director of the Centre for Genomic Pathogen Surveillance (CGPS) at the Pandemic Science Institute, University of <\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div> Amish Acharya<\/strong><\/p>\n\n Senior Scientific and Clinical Advisor to Executive Chair, Fleming Initiative<\/p>\n\n Dr Amish Acharya MD PhD is Senior Scientific and Clinical Advisor to Lord Darzi, the Executive Chair of the Fleming Initiative. He is an active clinician scientist with over a decade of experience in the UK\u2019s National Health Service, working as a vascular surgeon. As Lord Darzi\u2019s advisor he has been responsible for supporting the strategic positioning, fundraising activity and external relations for the Fleming Initiative, having helped lead on the development of a number of partnerships during his tenure. He has recently, been working on supporting the Initiative\u2019s work in data and AI, in particular, the infrastructural challenges faced when harnessing data-driven technologies at-scale. Damilola Adesuyi <\/strong><\/strong><\/p>\n\n Program Officer \u2013 Public Health, One Health and Development Initiative<\/p>\n\n Damilola Adesuyi is an early-career public health microbiologist applying behavioural science and the One Health approach to address antimicrobial resistance (AMR) and zoonotic diseases. He is Program Coordinator for AMR Mitigation and Antimicrobial Stewardship at the One Health and Development Initiative (OHDI), where he leads risk communication and AMR education and supports policy-relevant research. A Tsuha Global Fellow and 2024 RSTMH Early Career Grant recipient, Damilola has contributed to Nigeria\u2019s national AMR policy, including the Situational Analysis that informed NAP 2.0, and supported priority-setting for the National AMR Coordinating Committee. He has co-authored scientific and technical publications and leads award-winning youth-focused initiatives, including the African Youths for AMR Communication Project, recognised by the UK Health Security Agency. He currently serves on the Quadripartite Working Group on Youth Engagement for AMR and advocates for youth-led One Health action globally.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div> Raheelah Ahmad <\/strong><\/strong><\/p>\n\n Informed Policy co-lead, Fleming Initiative<\/p>\n\n Raheelah is a Professor of Health Systems at City St George\u2019s, University of London (CSGUL), and Informed Policy co-lead at the Fleming Initiative, Imperial College London, with over a decade of national and international applied research, capacity strengthening, and healthcare innovation implementation. She is Senior Mentor for the DHSC\/UK Government Fleming Fund Policy Fellows Programme, Knowledge Mobilisation Lead for the NIHR Health Protection Research Unit (HPRU) in Respiratory Infections and served as the Director for Global Engagement at the School of Health & Medical Sciences, CSGUL (2021-2025), contributing to strategic leadership. Raheelah leads Health Innovation & Change teaching on the MSc Health Management programme at CSGUL and is faculty for the EUCIC Implementation in Infection Prevention and Control course (Zurich).<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n Richard Alm<\/strong><\/p>\n\n Chief Scientist and Interim Chief of R&D, CARB-X<\/p>\n\n Richard joined CARB-X in 2019 following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company where he supported the progression of small molecule compounds from discovery through to late-stage clinical development and registration. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia at the University of Queensland and one in Canada at the University of Victoria in British Columbia. He currently serves as the Chief Scientist and Interim Chief of R&D at CARB-X, a global non-profit organization that supports a diverse and innovative pipeline of traditional and non-traditional products to prevent, diagnose, and treat infections caused by drug-resistant bacterial pathogens.<\/p>\n\n\n\n \u00a0<\/p>\n<\/details>\n<\/div><\/div> Gabriella Ak<\/strong><\/p>\n\n Clinical Microbiologist, Chairlady of the Infection Prevention & Control committee, Port Moresby General Hospital\u200b<\/p>\n\n Gabriella, a clinical microbiologist at Port Moresby General Hospital, plays a vital role in strengthening collaboration between laboratory and clinical teams to combat AMR in Papua New Guinea. A Fleming Fund Fellow, she advanced AMR diagnostics and data analysis, producing annual antibiograms that inform local clinical practice. As head of the hospital\u2019s Infection Prevention and Control Committee, she leads key IPC initiatives. With a Master\u2019s in Medicine (General Pathology) from UPNG and a Postgraduate Diploma in Medical Microbiology through PRIDA, Gabriella is a driving force in advancing AMR response and clinical excellence in PNG.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n<\/details>\n<\/div><\/div>
President, Science & Technology Australia
Founder and Chair, Ocean Decade Australia<\/p>\n\nRead bio<\/summary>\n
Recognising a crucial gap in Australian ocean governance in 2021 Jas co-founded and now Chairs Ocean Decade Australia. She is Director of Provenance Consulting, serves as President-elect of Science & Technology Australia and is a Member for the Cooperative Research Centres Advisory Committee for the Commonwealth Government of Australia.<\/p>\n<\/details>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\nPresenters<\/h2>\n\n\n
![\"Dame](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/07\/Sally-Davies-web-edited-1.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/08\/julia-gillard-web2.jpg\")
<\/div><\/figure>\n
Chair, Wellcome Trust<\/p>\n\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/12\/clark-helen-web.png\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2026\/01\/Sturchio-Jeffrey-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2026\/02\/cannan-chris-web.jpg\")
<\/div><\/figure>\n
First Assistant Secretary \u2013 Global Health and Education Division<\/p>\n\nRead bio<\/summary>\n
![\"Dr](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/07\/jean-pierre-nyemazi-web.jpg\")
<\/div><\/figure>\n
and Global Coordination and Partnership at WHO<\/p>\n\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/09\/halton-jane-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/11\/Wesselingh-Steve.png\")
<\/div><\/figure>\nRead bio<\/summary>\n
Professor Wesselingh is an infectious diseases physician and researcher. He undertook his undergraduate and doctoral training at Flinders University and his post-doctoral training at Johns Hopkins in the United States.
Until July 2023, Professor Wesselingh was the inaugural Executive Director of the South Australian Health and Medical Research Institute (SAHMRI). He was also a member of NHMRC Council, Chair of Research Committee, and the President of the Australian Academy of Health and Medical Sciences (AAHMS).
Between 2007-2011, he was Dean of the Faculty of Medicine, Nursing and Health Sciences at Monash University.<\/p>\n\n\n\n![\"Fiona](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/07\/Fiona-Reynolds-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2026\/02\/Tiensin-Thanawat-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2026\/02\/Kidd-Michael-web.png\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"Sir](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/09\/ONeill-Jim-web2.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"Rosemary](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/09\/RosemaryPortraits_144_crop.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/11\/ogilvie-leslie-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/09\/henry-skinner-web-2.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/12\/Aanensen-David-web.png\")
<\/div><\/figure>\nRead bio<\/summary>\n
Oxford. David also directs the WHO Collaborating Centre on Genomic Surveillance of AMR and the NIHR Global Health Research unit on Genomics and enabling data for surveillance of AMR, with key partners in Nigeria, India, Phillipines and Colombia.
David\u2019s team bridge the gaps between biology, computer science, and public health towards
applied genomic epidemiology. His research focuses on building digital infrastructure and
global networks for genomic surveillance, providing critical resources for understanding
pathogen evolution and combating Antimicrobial Resistance (AMR).<\/p>\n\n\n\n![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/11\/acharaya-amish-web.png\")
<\/div><\/figure>\nRead bio<\/summary>\n
<\/p>\n<\/details>\n<\/div><\/div>![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/11\/Adesuyi-Damilola-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/12\/ahmad-raheelah-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/11\/alm-richard-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n
![\"\"](\"https:\/\/wp.csiro.au\/amr-2026\/files\/2025\/12\/ak-gabriella-web.jpg\")
<\/div><\/figure>\nRead bio<\/summary>\n